Loading
HKSEHealthcareBiotechnology
Latest quote
HK$59.25
−HK$5.30 · -8.21%
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Latest quote
HK$59.25
−HK$5.30 · -8.21%
Regular session · HKT · Market data may be delayed.
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Day range
Current HK$59.25
52-week range
Current HK$59.25
Regular session · HKT · Market data may be delayed.
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Day range
Current HK$59.25
52-week range
Current HK$59.25
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.67B CNY | 5.72B CNY | 5.39B CNY | 3.21B CNY | 1.68B CNY |
| Cost of goods sold | 1.68B CNY | 1.54B CNY | 1.48B CNY | 844.62M CNY | 522.75M CNY |
| Gross profit | 4.98B CNY | 4.18B CNY | 3.92B CNY | 2.37B CNY | 1.16B CNY |
| Research and development | 1.52B CNY | 1.04B CNY | 1.12B CNY | 1.39B CNY | 1.02B CNY |
| Selling, general, and administrative | 2.65B CNY | 2.29B CNY | 2.14B CNY | 1.4B CNY | 800.87M CNY |
| Operating expenses | 4.17B CNY | 3.25B CNY | 3.29B CNY | 3B CNY | 1.82B CNY |
| Interest income | 18.3M CNY | 21.7M CNY | 8.15M CNY | 3.57M CNY | 2.69M CNY |
| Interest expense | 99.84M CNY | 122.89M CNY | 110.54M CNY | 105.67M CNY | 84.82M CNY |
| Depreciation and amortization | 346.05M CNY | 279.63M CNY | 279.63M CNY | 277.6M CNY | 200.18M CNY |
| Operating income | 817.12M CNY | 939.13M CNY | 631.7M CNY | −628.53M CNY | −665.25M CNY |
| Net income | 805.64M CNY | 820.47M CNY | 546.02M CNY | −695.26M CNY | −984.05M CNY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI Emerging Markets ETFIEMG2.79M0.00%163.33B USD0.09%$80.10-0.37%
iShares Genomics Immunology and Healthcare ETFIDNA1.28M0.49%256.44M USD0.47%$38.545-0.50%
State Street SPDR Portfolio Emerging Markets ETFSPEM712.48K0.00%17.7B USD0.07%$51.55-0.73%
Dimensional - Emerging Core Equity Market ETFDFAE339.88K0.00%10.17B USD0.29%$38.98-0.46%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM253.47K0.00%9.62B USD0.39%$39.40-0.66%
iShares MSCI China Small-Cap ETFECNS222.2K0.35%63.56M USD0.59%$27.66-1.22%
Dimensional World ex U.S. Core Equity 2 ETFDFAX188.46K0.00%12.61B USD0.28%$37.43-0.51%
iShares MSCI Emerging Markets Small-Cap ETFEEMS83.94K0.02%389.01M USD0.72%$74.355-0.92%iShares Core MSCI Emerging Markets ETFIEMGiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Emerging Markets ETFSPEMDimensional - Emerging Core Equity Market ETFDFAEDimensional - Emerging Markets Core Equity 2 ETFDFEMiShares MSCI China Small-Cap ETFECNSDimensional World ex U.S. Core Equity 2 ETFDFAXiShares MSCI Emerging Markets Small-Cap ETFEEMSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
